Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4013 A phase 3 randomised study of 177Lu-edotreotide or everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (LEVEL, GETNE-T2217)

Introduction: Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SSTR)-positive lung neuroendocrine tumors (NETs).

Conference:

Presenting Author:

Authors: García-Álvarez A, Garcia-Carbonero R, Anido U, Jimenez-Fonseca P, Del Olmo-García M,

Keywords: Lung NET, Peptide receptor radionuclide therapy,

#3603 Genetic tumor and blood profiling in the randomised controlled phase III COMPOSE trial comparing 177Lu-edotreotide and best standard of care for well-differentiated aggressive grade 2/3 gastroenteropancreatic neuroendocrine tumors

Introduction: COMPOSE is a randomised, controlled, open-label, Phase III trial in patients with well-differentiated aggressive G2/G3 (Ki-67 index 15−55%), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 177Lu-edotreotide targeted radionuclide therapy (TRT) will be compared with best standard of care (CAPTEM, FOLFOX or everolimus). Therapeutic strategies for high grade GEP-NETs demonstrate variable outcomes and currently there is a lack of tools to predict TRT efficacy and disease progression. Genetic profiling analysis is proposed to address this need.

Conference:

Presenting Author:

Authors: Capdevila J, Halfdanarson T, Halperin D, Herrmann K, Kong G,

Keywords: gastroenteropancreatic neuroendocrine tumor, targeted radionuclide therapy, bioinformatics, gene expression,

#3389 COMPOSE: Phase III trial of 177Lu-edotreotide versus standard of care in well-differentiated (WD) aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Therapeutic algorithm for well-differentiated (WD) high-grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors (G2 + G3 GEP-NETs) is not well established. Current ‘best standard of care’ include CAPTEM, FOLFOX and everolimus. Peptide Receptor Radionuclide Therapy (PRRT) could be useful in high grade NETs, however there is a lack of prospective evidence. 177Lu-edotreotide is an innovative radiolabeled somatostatin analogue with a favourable safety profile and efficacy. The ongoing Phase III trial COMPETE in G1 and G2 GEP-NETs is exploring the efficacy and safety of 177Lu-edotreotide, in comparison to everolimus.

Conference:

Presenting Author:

Authors: Hernando J, Halfdarnarson T, Halperin D, Reidy-Lagunes D, Kong G,

Keywords: neuroendocrine, NET, 177Lu-edotreotide, PRRT,